Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Universal STAR-T Cell in Generalized Myasthenia Gravis
NCT07714798Phase 1Not yet recruiting
- Sponsor
- Daishi Tian
- Start
- Jul 2026
- Primary completion
- Jul 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Universal STAR-T Cell Injection in myasthenia gravis (MG), sponsored by Daishi Tian. Primary endpoints: Adverse Events and Serious Adverse Events at 104 weeks and Dose-Limiting Toxicities at 28 days. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
Universal STAR-T Cell Injection
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT07714798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07714798.